Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS
Halozyme Therapeutics Inc. logo

Halozyme Therapeutics Inc.

Sector: Healthcare   

Industry: Biotechnology

44.71
 
USD
  
-0.68
  
(-1.50%)
Optionable: Yes  Market Cap: 5,577 M  90-day average vol: 1,032,151

Previous close: 45.39  Open: 45.36  Bid: 44.44  Ask: 46.25
52 week range    
31.86   
   46.16
Peers   
MNKD / 
LLY / 
BAX / 
PFE / 
SNY / 
Last updated: Monday 20th May 2024
52
MarketXLS Rank
40
Value
69
Technical
47
Quality

Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS

Get started today
Search for a stock

🎉 Exciting news! 🎉

You are invited to join our Discord Channel.

Interact, learn, and grow with experts in the markets!

Join our Discord

Metrics

Peers

StockDividendMarket Cap (B)PEPrice ($)

BAX

0.012943 B35.986.87

JNJ

0.0247450 B22.1171.06

LLY

0.0161238 B37.4243.55

MNKD

1 B-11.33.77

PFE

0.0302298 B15.153.21

SNY

Financials

HALO Income Statement

Annual
Dec-14Dec-15Dec-16Dec-17Dec-18Dec-19Dec-20Dec-21Dec-22Dec-23
Amortization of intangibles43 M74 M
Basic EPS from continuing operations-0.50.952.861.482.13
Basic EPS total0.03-0.810.46-0.01-0.50.952.861.482.13
Basic weighted shares outstanding123 M127 M128 M136 M287 M289 M136 M141 M137 M132 M
Cost of sales-23 M-29 M-33 M-31 M-10 M46 M43 M81 M139 M192 M
Depreciation-2 M-2 M-2 M-2 M-2 M4 M3 M3 M7 M11 M
Depreciation unreconciled43 M74 M
DepreciationAndAmortization-2 M-2 M-2 M-2 M-2 M4 M3 M3 M43 M74 M
Diluted EPS total-0.56-0.25-0.810.45-1.12-0.50.912.741.442.1
Diluted normalized net income/share-0.50.912.741.442.1
Diluted weighted shares outstanding122 M129 M128 M139 M144 M144 M141 M147 M141 M134 M
GainOnSaleOfPPE-5000.0-1 M772000.0
GeneralAndAdministrativeExpense-2 M-2 M-2 M-2 M-2 M77 M46 M50 M144 M149 M
Gross operating profit53 M106 M113 M285 M142 M150 M224 M362 M521 M637 M
Income before tax-68 M-32 M-102 M62 M-80 M-72 M129 M249 M249 M348 M
Income restructuring and M&A-1 M-1 M
Income taxes-6 M1 M-1 M537000.0-11000.0217000.0-154 M47 M67 M
InterestExpenseNonOperating6 M5 M20 M22 M18 M12 M20 M8 M17 M19 M
MiscOtherSpecialCharges1 M3 M8 M7 M5 M-20 M-2 M16 M
Net income from total operations-68 M-32 M-103 M63 M-80 M-72 M129 M403 M202 M282 M
NetIncomeCommonStockholders-68 M-32 M-103 M63 M-80 M-72 M129 M403 M202 M282 M
NetIncomeContinuousOperations-68 M-32 M-103 M63 M-80 M-72 M129 M403 M202 M282 M
NetNonOperatingInterestIncomeExpense-5 M-5 M-20 M-22 M-18 M-12 M-20 M-8 M-17 M-19 M
Normalized income275 M
Operating income-63 M-27 M-83 M81 M-69 M-68 M144 M276 M268 M338 M
Operating income before depreciation (EBITDA)-58 M-23 M-76 M87 M-61 M-57 M168 M265 M324 M453 M
OperatingExpense116 M133 M197 M204 M211 M218 M80 M86 M253 M299 M
Other income net-200000.0-1 M-3 M-8 M-7 M-5 M20 M2 M-16 M
OtherGandA-2 M-2 M-2 M-2 M-2 M77 M46 M50 M144 M149 M
OtherImpairmentOfCapitalAssets-200000.01 M577000.0
OtherOperatingExpenses-5 M-62 M-64 M-60 M-1 M-787000.0-791000.0
RentAndLandingFees-2 M-2 M-2 M-2 M-2 M3 M2 M
Research & development expense80 M93 M151 M151 M150 M141 M34 M36 M67 M76 M
ResearchExpense80 M93 M151 M151 M150 M141 M34 M36 M67 M76 M
RestructringAndMnAIncome-1 M-1 M
Revenue per share-2 M2 M14 M4 M43 M74 M
SalariesAndWages-15 M-21 M-26 M-31 M-36 M
Selling Gen & administrative expense36 M40 M46 M54 M61 M77 M46 M50 M144 M149 M
SellingAndMarketingExpense36 M40 M46 M54 M61 M
SellingExpense36 M40 M46 M54 M61 M
Special income/charges1 M1 M
Total Income available for interest expense (EBIT)-63 M-27 M-82 M84 M-62 M-61 M150 M256 M266 M367 M
Total common shares outstanding127 M129 M130 M143 M145 M138 M135 M138 M135 M127 M
Total net income-68 M-32 M-103 M63 M-80 M-72 M129 M403 M202 M282 M
Total ordinary shares127 M127 M127 M127 M127 M127 M127 M127 M127 M127 M
Total revenues75 M135 M147 M317 M152 M196 M268 M443 M660 M829 M
TotalExpenses93 M104 M163 M173 M201 M264 M123 M167 M393 M492 M
TotalRevenue38 M46 M53 M50 M152 M196 M268 M443 M660 M829 M
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.

MarketXLS is a complete Excel stock solution

Kevin Hsu

StockKevin.com

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel

Lloyd Lenase

Option Day Trader

MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.

Dave

Swing trader since 2011

I like to access historical closing prices on a particular date. That makes tracking performance easy.

Patrick Cusatis, Ph.D., CFA

Associate Professor of Finance - Penn State University